Iron overload coupled with low hepcidin levels are characteristics of hereditary haemochromatosis. To understand the role of transferrin receptor (TFR) and intracellular iron in hepcidin secretion Chinese hamster ovary transferrin receptor variant (CHO TRVb-1) cells were used that express iron-response-element-depleted human TFRC mRNA (TFRC∆IRE).
Introduction
Hepcidin is a liver-secreted, 25-mer peptide hormone responsible for maintaining iron homeostasis in the body [1] . Systemic iron elevation leads to increased levels of hepcidin that binds to ferroportin, the cellular iron-exporter, and induces internalisation and degradation of both hepcidin and ferroportin [2] . Thereby, it prevents cellular iron-efflux and regulates systemic iron levels. However, the iron-sensing mechanisms that lead to hepcidin secretion are unclear. A putative role of transferrin receptor (TFR)1 in modulating hepcidin expression was suggested [3] but its significance in transferrin-sensing and hepcidin induction has not been sufficiently emphasised. Likewise, even though an involvement of intracellular iron in the maturation of prohepcidin into bioactive hepcidin was postulated [4] , its function in hepcidin peptide secretion has not been sufficiently examined. This is partly because of lack of suitable cell lines that could consistently mimic the human hepcidin response to iron treatments. Also, majority of previous ex vivo iron supplementation studies and even some current investigations focussed on transcriptional regulation of hepcidin [5] and not on bioactive hepcidin peptide.
These issues have been addressed in the present study where holotransferrin (holo-Tf) induced hepcidin peptide secretion was examined in Chinese hamster ovary transferrin receptor variant (CHO TRVb-1) cells. These cells lack endogenous TfR1 and express iron response element (IRE)-depleted human TFRC mRNA (TFRC∆IRE) [6] . Due to this unique feature it was hypothesised that upon holo-Tf treatment, these cells would bypass the IREdependent TFRC mRNA regulation by iron [7] and show increased iron-uptake. The effect of this on hepcidin secretion could be studied and compared with HepG2 cells that possess ironregulated TFRC mRNA. Accordingly, after defining the iron saturation of the iron source and iron content of the treatment medium, the effect of holo-Tf treatment on cell-surface TFR1, intracellular iron content and hepcidin secretion were studied over short and long timeperiods. Furthermore, mRNA expression of CHO-endogenous slc40a1 and human TFRC was examined under holo-Tf excess to further understand cellular iron regulation in the absence of iron-regulated TFRC. To enable this, the previously unknown sequence of slc40a1 in the CHO TRVb-1 cells was characterised.
Materials and Methods

Cell culture
Wild type (Wt) CHO and CHO TRVb-1 clone B6, donated by Professor Keith Caldecott (University of Sussex, UK) and Dr. Heinz Zoller (University of Innsbruck, Austria), respectively, were maintained in Ham's F12 nutrient mixture (1X) (Invitrogen, UK) with 2 mM glutamax (Fisher Scientific,UK), 10 % foetal calf serum (FCS) (Biosera, UK) and 1 % antibiotic/antimycotic solution (100X) (Fisher Scientific, UK). HepG2 cells (Health Protection Agency, UK) were maintained in Eagle's Minimum Essential Medium (EMEM) (Sigma-Aldrich, UK).
Iron treatment studies
Apo-Tf was iron-loaded using 0.1 M ferric citrate and iron saturation of 5 g/L holo-Tf was confirmed by polyacrylamide gel electrophoresis using a 6 M urea gel [8] . Iron concentration in holo-Tf treatment medium was determined by ferrozine assay [9] . Cells were seeded at a density of 5 X 10 5 cells in a 6-well plate and maintained until 60 % -70 % confluent. After washing with phosphate buffered saline (PBS) (Invitrogen, UK), cells were treated with serum-free EMEM (0 g/L) or 5 g/L holo-Tf from 30 minutes (min) to 24 h and various parameters were assessed, as described below.
Detection of human transferrin receptor at mRNA and protein levels in CHO TRVb-1 cells
To detect TFRC transcripts in CHO cells, PCRs were conducted with cDNA as template and primers listed in the succeeding section. Human TFR1 protein in the CHO TRVb-1 cells was confirmed by immunoblotting. Cell pellet was mixed with 2X Laemmli buffer and loaded on 10 % SDS gels (BIO-RAD, UK.) After electrophoresis, proteins were transferred to a PVDF membrane and blocked with 10 % fat-free milk in PBS for 1 h at room temperature (RT).
Membranes were probed with primary human TFR1 antibody 3B82A1 (Thermo scientific, UK) [1:2000] for 1 h at RT and then incubated with a rabbit anti-mouse HRP-conjugated secondary antibody (Dako Ltd, UK) [1:1000] for 1 h at RT. Bands were visualised using ECL™ Western Blotting Detection Reagents (GE healthcare, UK) on X-ray film.
For analysis of cell-surface TFR1 expression, cells were harvested using TrypLE Express (ThermoFisher Scientific, UK), followed by centrifugation for 4 min at 89 x g. Cells were suspended in PBC (PBS containing 0.15 % BSA and 1 mM calcium chloride) and transferred to a 96-well plate (2 X 10 5 cells per well) and centrifuged at 1,260 x g for 30 sec. To each well, 20 µL of 16 mg/mL blocking IgG was added. Human transferrin receptor antibody (Abcam, UK) [5 µg/mL in PBC)] was added to each test well and PBC was added to the control wells. Cells were incubated for 45 min on ice. Following washing, the cells were incubated with 10 µg/mL of FITC-labelled secondary antibody STAR9B rabbit F (ab')2 antimouse IgG (ABD Serotec, UK). After incubation for 30 min on ice, cells were washed with PBC again. Cell layer at the bottom of each well was resuspended in 400 µL of PBS and TFR1 expression was analysed by flow cytometry [10] .
Determination of intracellular iron content and hepcidin peptide levels and mitochondrial activity
Cellular iron content, as determined by the ferrozine assay [9] , was expressed as nmoles of iron per mg of protein, as quantified by the Bradford method. The ferrozine assay can detect levels from 2 to 300 µM and compares favourably to atomic absorption spectroscopy [9] and and ICP-MS [11] . The concentration of hepcidin peptide secreted in the cell media was measured as described by Busbridge et.al [12] . Here, using a rabbit anti-human hepcidin antibody, plasma hepcidin range from 1.1-55 ng/mL, with a median of 10.8 ng/mL in healthy controls, while the limit of detection is 0.6 ng/mL and linearity is up to 200 ng/mL [12] . The mitochondrial activity was assessed using the MTT assay [13] . [14] , TGTTTCTGGTAGAGCTCTAT (F) and GATATAGCAGGAAGTGAGAA (R) for human SLC40A1 and GCCAAAAGGGTCATCATCTC (F) and GGTGCTAAGCAGTTGGTGGT (R) for GAPDH [15] were used. RNA was extracted using the TRI reagent (Sigma-Aldrich, UK), reverse transcription and cDNA synthesis was performed using QuantiTect reverse transcription kit (Qiagen, UK) and PCRs were performed using Taq PCR master mix (Qiagen, UK). All PCR products were sequenced to confirm product identity. Prior to sequencing, amplicons were electrophoresed on 1 % agarose gel (Web Scientific, UK) to confirm product size and purified using PCR product purification kit (Qiagen, UK). Sequencing was conducted at the Wolfson Institute for Biomedical Research (University College London, UK). Gene expression was analysed through real-time PCR using Qiagen's Quantifast SYBR green kit in Rotor-gene Q machine (Qiagen, UK) and results were analysed using Rotor-gene software series 1.7. Data was expressed as 2 -∆∆Ct [16] .
Characterisation of slc40a1 sequence in CHO TRVb-1 cells DNA was extracted using the isopropanol-ethanol precipitation method [17] . To characterise the previously unknown slc40a1 sequence in CHO TRVb-1 cells, genomic similarities between related species were assessed (supplementary Table 1 ) and "PCR walking" was used (supplementary information). Characterised CHO-slc40a1 gene sequence was translated to its protein sequence (referred as CHO-ferroportin) by using the TRANSLATE tool (http://web.expasy.org/translate) and compared with ferroportin sequences of human, mouse and rat (supplementary Table 2 ) by using ClustalW2 (www.ebi.ac.uk).
Bioinformatics analysis of hepcidin peptide sequences
To assess peptide sequence similarities between human and Chinese hamster, multiple sequence alignments were created via CLUSTAL O (1.2.1) available via UniProtKB (supplementary Table 2 ).
Statistical analysis
Data was analysed by using one-way or two-way ANOVA, accompanied by post-hoc analysis by Tukey's test using the software SPSS, version 19. The level of significance was set at p<0.05.
Results
Characterisation of CHO TRVb1-cells in basal conditions
TFR1 expression: Presence of human TFRC mRNA and absence of CHOendogenous Tfrc mRNA in CHO TRVb-1 cells was confirmed (Fig.1a) . Here, only wt CHO cDNA formed product with primers for CHO-endogenous Tfrc (lane 1). As expected, CHO TRVb-1 cDNA did not form product with primers for CHO-endogenous Tfrc but formed product with primers for human TFRC (lanes 3 and 4, respectively). Human TFR1 protein in the CHO TRVb-1 cells showed expected bands of approximately 180 kDa (lane 1) and 85-90 kDa (lane 2) under non-reducing and reducing conditions, respectively (Fig.1b) , as previously observed [18] . Also, the CHO-TRVb1 cells showed significantly higher levels of cell-surface TFR1 than HepG2 cells (2.2-fold; p<0.01) (Fig.1c) .
Intracellular iron content and hepcidin secretion: Under basal conditions, CHO
TRVb-1 cells maintained intracellular iron content over time and did not differ significantly from HepG2 cells (Fig.2a) . Hepcidin secretion in CHO TRVb-1 cells declined over time from 30 min to 2 h (p<0.05), followed by substantial reduction at 24 h (3.6-fold; p<0.01), while the HepG2 cells showed constant hepcidin levels (Fig.2b) . The CHO TRVb-1 cells secreted significantly lower levels of hepcidin than HepG2 cells at 2 h (p<0.04) and 24 h (p<0.02). (Fig.4b) . However, the levels significantly increased from 4 h to 24 h (p<0.05) and restored iron levels to that observed at earlier time points. Iron levels did not majorly differ from the HepG2 cells, except at 4 h (p<0.02) (Fig.4b ).
Iron supplementation studies in CHO
Hepcidin levels: Holo-Tf deprivation in CHO TRVb-1 cells (Fig.4c ) caused a significant decline in hepcidin secretion over time from 30 min to 24 h (2.8-fold; p<0.01). The levels were similar to HepG2 cells, except at 4 h where the levels in CHO TRVb-1 cells were higher than levels in HepG2 cells (1.9-fold; p<0.02). Upon holo-Tf treatment, the CHOTRVb-1 cells exceeded basal hepcidin secretion levels at all time-points (p<0.02), but it decreased from 30 min to 24 h (1.8-fold; p<0.01), unlike the HepG2 cells that maintained constant levels (Fig.4d) . Hepcidin levels in CHO TRVb-1 cells were similar to HepG2 cells, except at 24 h where the CHO TRVb1 cells secreted significantly lower levels than HepG2 cells (1.7-fold; p<0.02).
Gene expression analysis: Holo-Tf deprivation in CHO-TRVb1 cells significantly
increased TFRC expression at 4 h (3.3-fold; p<0.05) and significantly reduced slc40a1 expression at 2 h (p<0.03) and 24 h (p<0.05) (Fig.5a ). Holo-Tf treatment to CHO TRVb1 cells significantly increased TFRC expression at 2 h (3.2-fold; p<0.03) and 4 h (5.9-fold; p<0.05) (Fig.5b) slc40a1 expression was significantly elevated at 2 h (2.2-fold; p<0.05) and 4 h (3.4-fold; p<0.03), which followed a substantial decrease at 24 h (p<0.01). In the HepG2 cells, holo-Tf deprivation caused an insignificant increase in TFRC expression (3.6-fold; p=0.09) and a significant decrease in SLC40A1 expression at 24 h (p<0.03) (Fig.5c ).
Following holo-Tf treatment, TFRC expression significantly increased at 2 h (3-fold; p<0.01) whereas SLC40A1 expression significantly decreased at 4 h (p<0.05) (Fig.5d ).
Mitochondrial activity:
The CHO TRVb1 and HepG2 cells did not show any major change in mitochondrial activity under holo-Tf deprived and supplemented conditions (Fig.6 ).
Characterisation of slc40a1 in CHO TRVb1-cells
To enable gene expression analyses, the previously unknown sequence of CHO-endogenous slc40a1 was partially characterised (Fig.7) . These characterised sequences displayed very high percentage similarities with corresponding slc40a1 sequences in human (>88%), mouse (>90%) and rat (>90%) (Fig.7b) . Partial alignment of the sequence is shown in supplementary Fig.1 . The characterised CHO-slc40a1 sequence was translated into a protein sequence and compared with ferroportin sequences in other species. Data showed conservation of many functionally significant domains in the proposed transmembrane region and the hepcidin binding region in ferroportin (Fig.7c) . Particularly conserved were N144 and V162, which if mutated, exhibit hepcidin insensitivity. The position of C326 in relation to other amino acids is also conserved in the proposed hepcidin binding region, lying outside the transmembrane region and therefore appears to be consistent with its role in binding to hepcidin. K253, Y302 and Y303, which are involved in ferroportin internalisation and degradation upon hepcidin binding are conserved in this characterised CHO-slc40a1 sequence and are located in the same position relative to other amino acids as in human, mouse and rat ferroportin [19] . Also, cysteines which form disulphide bonds and usually play a significant role in the folding and stability of proteins [20] , are well conserved.
Bioinformatics analysis of hepcidin
Peptide sequence similarities between hamster and other species were assessed. The two predicted hepcidin isoforms in Chinese hamster [21] bear 84 % sequence similarity with each other (Fig.8a) and the terminal 25-mer region bears 84 % sequence similarity with human hepcidin-25 (Fig.8b) . Specifically, the first eleven amino acids at its N-terminus are identical to corresponding positions in human hepcidin-25, except that threonine at position 2 in human hepcidin-25 is replaced by serine, which has a side chain similar to threonine. Moreover, there is 100 % conservation of the eight functionally and structurally significant cysteines [22] ( Fig.8b) .
Discussion
Here, the effect of excess holo-Tf on intracellular iron levels and hepcidin secretion was [24] or down regulation of hepcidin mRNA [25] . On the other hand, when 100 µM holo-Tf (approximately 4 g/L) was used for treatment, an increase in hepcidin mRNA expression was observed [26] . It is also important to note that non-Tf bound iron (NTBI) may play a role in iron uptake. However, pathways for NTBI uptake are less clearly defined compared to TBI uptake. In addition, several previous studies with NTBI showed no effect [1, 24] or even down regulation [15, 25, 27] of hepcidin mRNA. Moreover, the holo-Tf treatment medium was prepared in serum-free Eagle's Minimal Essential Medium (EMEM) that is deprived of inorganic iron sources. This was confirmed by the ferrozine assay, which showed no detectable iron levels in this medium, denoted as 0 g/L (supplementary Fig. 2b) , while it showed approximately 6 µM in a FCS (10%)-supplemented EMEM. Thus, the current findings are only based on holo-Tf treatment.
Cellular iron regulation and characterisation of hepcidin response
Human TFRC at mRNA and protein levels were confirmed in CHO TRVb-1 cells (Fig.1a and   1b ). The cells expressed 2.2-fold higher basal levels of cell-surface TFR1 than HepG2 cells (Fig.1c) . Following 5 g/L holo-Tf treatment, the HepG2 cells significantly decreased cellsurface TFR1 expression over time (Fig.3c) and demonstrated an expected iron-regulated response where TFRC transcripts are sensitive to intracellular iron sufficiency due to the IRE region [7] and subsequently decrease cell-surface TFR1 to avoid further iron-uptake, as confirmed here. Contrastingly, the CHO TRVb-1 cells showed constantly elevated expression despite prolonged extracellular holo-Tf excess; a dysregulated characteristic of cell-surface TFR1 in these cells demonstrated in this study for the first time (Fig.3c ). This dysregulation due to TFRC∆IRE was also reflected at mRNA level where despite excess extracellular holoTf, TFRC mRNA expression significantly increased at 2 h and 4 h (Fig.5b) .
Although the constitutively high expression of cell-surface TFR1 (Fig.3c) and TFRC∆IRE together indicated a potential for increased iron-uptake, surprisingly, the CHO TRVb-1 cells neither showed higher intracellular iron levels than HepG2 cells under basal conditions (Fig.2a) nor majorly increased iron-uptake upon holo-Tf supplementation (Fig.4b) , contrary to the expected. This could be attributed to the elevated slc40a1 expression, as observed at 2 h of holo-Tf treatment to promote cellular iron-efflux [28] and circumvent any potential increase in iron content caused by increased TFRC mRNA expression at the same time (Fig.5b) . Accordingly, at 4 h of holo-Tf treatment, a 3.2-fold increase in slc40a1 expression corresponded to a 2.2-fold decrease in intracellular iron content (Fig.5b and Fig.4b ). Such elevations in slc40a1 expression are consistent with the iron-sensitive feature of the IRE region on slc40a1 mRNA [29] . This feature prevented cellular iron overload in CHO TRVb-1 cells and did not allow iron levels to exceed beyond that in HepG2 cells, which showed constant levels of SLC40A1 mRNA expression (Fig.5d) .
Interestingly, the CHO TRVb-1 cells are similar to cancer cells that also over-express cell-surface TFR1 to acquire iron for cell survival, growth and proliferation [30] . However, while the human breast cancer cells showed reduced ferroportin expression compared to nonmalignant cells [31] , presumably to retain intracellular iron, the CHO TRVb-1 cells differed and showed elevated slc40a1 expression, aiming for iron-efflux (Fig.5) . Thus, unlike cancer cells, the CHO-TRVb1 cells exhibited a fascinating regulatory phenomenon where scl40a1 maintained intracellular iron-homeostasis in presence of excess extracellular holo-Tf and abundant cell-surface TFR1, while TFRC mRNA was incapable of contributing to intracellular iron-sensing due to TFRC∆IRE. The overall aim of protecting the cells from excess-iron-mediated toxicity was achieved, as confirmed through the MTT assay, which showed no signs of cell toxicity (Fig.6) .
Here, we presented novel data where the CHO TRVb-1 cells secreted hepcidin under basal conditions; and following holo-Tf treatment, exceeded basal levels at all time-points ( Fig.2b and Fig.4d ). This resembled the human response to excess systemic iron levels [1] and suggested that these cells were suitable to study holo-Tf-induced hepcidin responses. The antibody utilised detects the N-terminal 14 amino acid region of human hepcidin-25 [12] , (Fig. 8b, amino acids in bold) . Here, 12 out of the total 14 amino acids are identical to the corresponding region in hamster hepcidin (Fig. 8b, highlighted grey) . Moreover, in position-2 of human hepcidin-25, threonine in human is replaced by a structurally and functionally similar amino acid serine in hamster. This leaves only one dissimilar amino acid at position 12. Such high level of similarity in the antibody binding region of hepcidin-25 fully supports the successful detection of hamster hepcidin by this method. The method used here has also been successfully used to detect hepcidin in rhesus monkeys [32] .
Under basal conditions, the CHO TRVb-1 cells secreted significantly lower levels of hepcidin than HepG2 cells (Fig.2b) . Since HepG2 cells are of hepatic origin whereas CHO TRVb-1 cells are ovary-derived, this data is consistence with the tissue-specific nature of hepcidin, where, in human and animals, hepcidin is predominantly secreted by liver hepatocytes with lower amounts being secreted by other tissues [33] , however the peptide expression level has been reported higher in rat kidney than human kidney by immunoblot analysis (Kulaksiz et al., 2005). Also, overexpressed TFR1 expression on the cell-surface may have disturbed its physiological ratio with HFE and TFR2, the hepcidin inducing proteins [34] , thereby causing lower hepcidin secretion under basal conditions. However, upon holo-Tf treatment, hepcidin levels in CHO TRVb-1 cells matched the levels in HepG2 cells, at least up to 4 h (Fig.4d) , which indicated that tissue-specificity was overruled and hepcidin response to holo-Tf treatment governed. This may have occurred via two mechanisms; first, upon binding of holoTf to TFR1, the TFR1-bound HFE may be displaced and free to bind to TFR2 to induce hepcidin [3] and second, due to the predominance of response-specific factors over tissuespecific factors [35] . Since, the expected intracellular iron overload was not achieved, exactly how and to what extent intracellular iron levels modulate hepcidin secretion remains to be elucidated.
Characterisation of CHO-slc40a1 and bioinformatics study of hepcidin peptide sequences
In order to study iron-efflux in CHO TRVb-1 cells and cellular iron regulation via real-time PCR, genomic similarities between species were examined (supplementary Table 1 ) and partial characterisation of the previously unknown slc40a1 sequence in CHO TRVb-1 cells was achieved (Fig.7a and 7b) . As expected, the characterised slc40a1 sequences in CHO TRVb-1 cells bore more than 88 % sequence similarities with the corresponding sequences of human, mouse and rat (Table 1 ) and were subsequently used to design primers for gene expression analysis ( Supplementary Fig.1, Fig.5a and 5b) . Comparison of the characterised and then translated CHO-slco40a1 sequence with ferroportin sequences from other species showed an overall 92 % similarity. Several amino acids in the functionally significant domains such as the proposed transmembrane region and hepcidin binding region are conserved, as presented here for the first time (Fig.7c) . Overall, the data indicates that the sequence of ferroportin is well conserved amongst species.
The two hepcidin isoforms of Chinese hamster [21] show high sequence similarity with human hepcidin-25 (Fig.8b) . This is particularly in the N-terminal region that is important for its interaction with ferroportin, the furin cleavage site on prohepcidin that releases bioactive hepcidin and the 8 cysteine residues, which are believed to have structural and functional significance [22] .
Conclusion
Despite the substantially higher levels of cell-surface TFR1, intracellular iron overload was 
-----------------------------------------------------------Rat MTKSRDQTHQEGCCGSLANYLTSAKFLLYLGHSLSTWGDRMWHFAVSVFLVELYGNGLLL 60 Hamster --------------------------------------------------------SLLL 4
Human TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKHEL 120 Mouse TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKNEL 60 Rat TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKNEL 120 Hamster TAVYGLVVAGSVLVA-----------------QTSLVVQNVSVILCGIILMMVFLHKNEL 47 ************** *************************:** Human LTMYHGWVLTSCYILIITIANIANLASTATAITIQRDWIVVVAGEDRSKLANMNATIRRI 180 Mouse LTMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 120 Rat LNMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 180 Hamster LTMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 107 *.******** **********************************:**:**:******** N144H V162∆ Human DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYVLLWKVYQKTPALAVKAGLK 240 Mouse DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAALK 180 Rat DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAALK 240 Hamster DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAVLK 167 ****************************************.**************** ** Human EEETELKQLNLHKDTEPKPLEGTHLMGVKDSNIHELEHEQEPTCASQMAEPFRTFRDGWV 300 Mouse VEESELKQLTSPKDTEPKPLEGTHLMGEKDSNIRELECEQEPTCASQMAEPFRTFRDGWV 240 Rat VEESELKQLTSPKDTEPKPLEGTHLMGEKDSNIRELECEQEPTCASQIAEPFRTFRDGWV 300 Hamster VEEAELKQLNLPKDTEPKSLEGTHLMGEKDSNIRELEHEQESTCASQIAEPFRTFRDGWV 227 **:*****. ******.******** *****:*** ***.*****:************ K253 Human SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAF 360 Mouse SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAF 300 Rat SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSVLMGASAITGIMGTVAF 360 Hamster SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLS----------------------265 ************************************** Y302,Y303 C326 
Species
